Protagonist Therapeutics
J&J’s Icotrokinra (JNJ-2113) Achieves Significant Success in Phase 3 Trials for Moderate to Severe Plaque Psoriasis
JNJ-2113, icotrokinra, IL-23 receptor antagonist, plaque psoriasis, Phase 3 clinical trials, Johnson & Johnson, Protagonist Therapeutics